SECURITIES & EXCHANGE COMMISSION EDGAR...

SECURITIES & EXCHANGE COMMISSION EDGAR FILING

DYADIC INTERNATIONAL INC

Form: 8-K

Date Filed: 2019-11-25

Corporate Issuer CIK: 1213809

© Copyright 2019, Issuer Direct Corporation. All Right Reserved. Distribution of this document is strictly prohibited, subject to the terms of use.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (date of earliest event reported): November 21, 2019

Dyadic International, Inc.(Exact name of registrant as specified in its charter)

Delaware(State or other jurisdiction of incorporation or organization)

000-55264(Commission File Number)

45-0486747(I.R.S. Employer Identification Number)

140 Intracoastal Pointe Drive, Suite 404Jupiter, FL 33477

(Address of principal executive offices and zip code)

(561) 743-8333(Registrant’s telephone number, including area code)

N/A (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

❑ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

❑ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

❑ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

❑ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act

EDGAR Stream is a copyright of Issuer Direct Corporation, all rights reserved.

Title of each class Trading Symbol(s) Name of each exchange on which registeredCommon Stock, par value $0.001 per share DYAI The NASDAQ Stock Market LLC

Item 8.01 Other Events

On November 25, 2019, Dyadic International, Inc. (the “Company”) announced that data presented at the annual PEGS Europe Protein & Antibody Engineering Summit demonstrated that its C1 strain has been successfully glyco-engineered to impart the core human like G0 glycan structure at high levels.

The G0 glycosylation data was presented by Markku Saloheimo, Ph.D., from the VTT Technical Research Centre of Finland Ltd (“VTT”) at the PEGS conference in Lisbon, Portugal on Thursday, November 21, 2019. The scientificresults are outlined in the presentation entitled ''Novel Highly Productive Production System for Biotherapeutics: Filamentous Fungus Myceliophthora thermophila''.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibit is being furnished herein:

ExhibitNumber Description

99.1 Press Release dated as of November 25, 2019.99.2 VTT presentation entitled ''Novel Highly Productive Production System for Biotherapeutics: Filamentous Fungus Myceliophthora thermophila''

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 25, 2019

Dyadic International, Inc.

By: /s/ Mark A. EmalfarbName: Mark A. EmalfarbTitle: Chief Executive Officer


ex991dyadicannouncesac.htm

vttpresentsatpegslisbonr.htm

Novel Highly Productive Production System for Biotherapeutics: Filamentous Fungus Myceliophpthora thermophila C1 Markku Saloheimo VTT Technical Research Centre of Finland Ltd PEGS Lisbon Conference, November 21, 2019 1


VTT Cell Factories for Recombinant Protein Production Host systems • Prokaryotic - Escherichia coli • Yeasts - Saccharomyces cerevisiae - Pichia pastoris Trichoderma reesei • Filamentous fungus - Trichoderma reesei Nicotiana benthamiana - Myceliophthora thermophila • Higher eukaryotes - Plants and plant cell cultures Pichia pastoris From gene to protein We can provide the customer with complete tailor-made service Saccharomyces cerevisiae for producing a protein of interest. Escherichia coli


Myceliophthora thermophila (Thermotelomyces heterothallica) � Thermophilic fungus originally isolated from alkaline soil in Russia � Designated earlier as Chrysosporium lucknowense and currently as Myceliophthora thermophila � Isolated for its ability to produce neutral/alkaline cellulases for use in textile applications � Dyadic Announced Successful Completion of Sequencing of C1 Fungal Genome (May/2005) � Genome sequenced 2011 by JGI (Nat. Biotechnol. 2011 Oct 2;29(10):922-7) � Dyadic International Inc. has developed an industrially proven expression system based on the fungus Myceliophthora thermophila, C1 Expression System o Improved production strains with unique morphology o C1 received a Generally Recognized As Safe (GRAS) designation from the FDA, with no viruses detected, no mycoplasmas, and no detectable mycotoxins (FDA, 2009) o Highest production level of enzymes >120 g/L o Highest production level of an individual recombinant enzyme 80 g/L 21.11.2019 VTT – beyond the obvious


Our Goal To further develop C1 into efficient gene expression system of biologic vaccines and drugs, to help speed up the development, lower production costs and improve the performance at flexible commercial scales. Efficient Expression Reducing Proteolytic Glycoengineering Activity � Library of promoters, carrier � Generation of humanized proteins, signal sequences and terminators � Identification of key proteases protein-glycan structures � Deletion of protease genes � Synthetic Expression System � Engineering a G0-glycan (SES) � Characterization and utilization producing C1 � Dual vectors of protease deletion strains � Split-marker technology � Marker recycling � Site-specific or random integration 21.11.2019 VTT – beyond the obvious 4


Efficient Expression C1 Fermentation Technology � Easily available defined media � No need for induction components – glucose, salts, micro � Protein is secreted to the media Fed-batch and macro elements, AA and vitamins � 20-30 % biomass Process � Fed-batch technology with glucose � pH: 5-8, Temp: 20 - 45°C feeding � 1L to 500,000 L fermentation scale � Low viscosity culture due to morphology changes (propagule) From MTP to Large scale; productivity of mAbs (example) 24-wells MTP – 1 mg/4ml 1L fermentor – 1.7 g/l/d 30L fermentor – 2.4 g/l/d 21.11.2019 VTT – beyond the obvious 5


Efficient Expression VTT Synthetic Expression System (SES) � Constitutive and extremely high-level expression permits use of any production conditions � Expression level is tunable by changing the number of sTF binding sites � Has been shown to function in multiple organisms: yeasts, filamentous fungi, plants and mammalian cells Rantasalo A et al., A universal gene expression system for fungi. Nucleic Acids Res. 2018 Oct 12;46(18) 21.11.2019 VTT – beyond the obvious 6


Efficient Expression C1 Expression Technology Different genetic modification methods can be Transformation applied: efficiency � Single site directed integration � 2 sites directed integration � Random integration � Episomal vectors – Transient expression system � Transformation procedure based on chemical (PEG) method with protoplasts or electroporation � Frequencies for 1µg DNA: • >20 transformants for site specific integration • Up to 100 transformants for random integration • ~13,000 transformants for telomeric vector transformation 7


Reducing Proteolytic Activity Isolation and identification of extracellular proteases Protease activity assays Fermentation Culture supernatant Affinity Chromatography Analysis of fractions Spiking with target proteins Zymogram gels with target protein Protease A Protease B Protease C LC-ESI MS/MS Fractions with Protease D proteolytic activity Protease E 21.11.2019 VTT – beyond the obvious 8


Reducing Proteolytic Activity C1 Protease library in Pichia pastoris � More than 50 proteases were expressed individually in Pichia pastoris � Culture supernatants of each strain expressing a C1 protease were tested in spiking experiments Identification of critical proteases which are problematic for many sensitive target proteins Vaccine Antigen (3h incubation) Fc-fusion protein (1h incubation) std std ctrl ctrl ctrl fusion Pichia supernatants expr. 14 individual C1 proteases Pichia supernatants expr. 15 individual C1 proteases - Strain Buffer Antigen Strain Fc * * * * * 21.11.2019 VTT – beyond the obvious 9


Reducing Proteolytic Activity C1 Lineage of protease deficient strains DNL104 4xΔ Systematic deletion of protease genes based on: � Isolation and identification of extracellular proteases DNL110 5xΔ � C1 protease library in Pichia pastoris � Effect of different protease inhibitors on protease activity DNL115 6xΔ DNL145 12xΔ � mRNA sequencing data � Protease gene annotation DNL120 7xΔ DNL140 11xΔ DNL121 7xΔ DNL135 10xΔ DNL125 8xΔ DNL131 9xΔ 21.11.2019 VTT – beyond the obvious 10


Reducing Proteolytic Activity Total extracellular protease activity is greatly reduced in C1 protease deficient strains � Direct fluoresence-based assay with casein substrate � The activity in the 8xΔ strain is reduced over 50-fold compared to the 1xΔ strain (fermentation cultures) � The activity in the 10xΔ strain is reduced 10-fold compared to the 4xΔ strain (24-well plate cultures) 80 70 60 50 40 30 20 10 0 Δ4 Δ5 Δ6 Δ7 Δ8 Δ9 Δ10 Fermentation culture MTP culture 21.11.2019 VTT – beyond the obvious 11


Protease Deletions are Improving Stability and Production of a Fc-fusion protein 5xΔ 6xΔ 10xΔ 11xΔ 0h 4h o/n 0h 4h o/n 0h 4h o/n o/2n 0h 3h o/n o/2n Yellow full-length Target protein was spiked into the culture supernatant Red degradation product of the different protease deletion strains 21.11.2019 VTT – beyond the obvious 12


Reducing Proteolytic Activity Protease deletion strains are improving stability of target proteins - Difficult-to-express protein Vaccine antigen 9xΔ 10xΔ 0h 3.5h o/n o/2n 0h 3.5h o/n o/2n std Target protein spiked into the culture supernatant of the protease deletion strains 21.11.2019 VTT – beyond the obvious 13


Glycoengineering Advantage of C1 over Yeast and CHO � C1 glycan structure is more mammalian like than typically in yeasts � The native C1 glycans are mostly high mannose type (Man3-Man9) including some hybrid glycans � Less engineering steps needed for C1 � Stable genome - defined glycan structure is stable from culture to culture and batch to batch � We aim at defined mammalian glycan forms G0, G0F, G2 and G2F in our glycoengineering efforts Typical Yeast Glycan Structure Dyadic C1 Glycan Structure Targeted Mammalian Glycoform Structures Man30-50 Man3-9 G0 G0F G2 G2F 14


Two main approaches to gain high Man3 � Man3 is the important precursor of G0 glycans ALG3 � Two approaches for high Deletion Man3: 1. Deletion of alg3 and over-expression of Mannosidase I 2. Deletion of alg3 and alg11 Flippase is the membrane protein enabling turning of the lipid-linked Asn Asn Adapted from Stanley et al., 2008, N- oligosaccharide to ER glycans. In: Essentials in Glycobiology. Varki et al, eds.) lumen side Man3 G0 ALG11 VTT – beyond the obvious Deletion 15


Alternative approach for G0: classical animal pathway The animal glycan modification pathway coud be built into C1 � Requires expression of Mannosidase I, GNT I, G0 Mannosidase II and GNT II to gain G0 glycans � Is more complicated than alg3 or alg3/alg11 approaches � Not pursued in C1 presently Modified from Nagae and Yamaguchi, Int. J. Mol. Sci. 2012, 13(7), 8398-8429. 21.11.2019 16


The effect of alg3 deletion in C1 Wild type strain Alg3 deletion strain � The alg3 gene was deleted by replacing it with a marker gene. Glycans on native proteins were analyzed � The glycan pattern became much more simple • All higher MW glycans and hybrid glycans were omitted • Substantial amounts of Hex6, Man5 and Man4 glycans remained – further engineering along this strategy is in progress 21.11.2019 VTT – beyond the obvious 17


Applying alg3-alg11 deletion strategy to produce G0 glycans Alg3-alg11 deletion + GNT1+2 Alg3 deletion strain RT Glycoform Area Relative (Abundance) Abun (%) 10,48 M3 30,93 1,63 12,46 M3GlcNac 85,79 4,52 14,21 G0 1781,79 93,85 sum 1898,51 100,00 � The alg11 gene was deleted from an alg3 deletion strain. Simultaneously heterolougus GNT1 and GNT2 were expressed from the alg11 locus. Glycans on native proteins are shown. � G0 glycan levels of up to 95% have been reached with this strategy. In addition to G0, only Man3 and GlcNAcMan3 remain in the glycan pattern. � Different Golgi localization signals for GNT1 were tested. 11/21/2019 VTT – beyond the obvious 18


The effect of flippase expression No flippase o/e Expression of flippase 1 Expression of flippase 2 RT Glycoform Area Relative RT Glycoform Area Relative RT Glycoform Area Relative (Abundance) Abun (%) (Abundance) Abun (%) (Abundance) Abun (%) 10,48 M3 69,34 7,05 10,48 M3 116,77 2,84 10,48 M3 259,86 3,00 14,21 G0 914,85 92,95 12,46 M3GlcNac 95,17 2,32 12,46 M3GlcNac 248,09 2,86 14,20 G0 8162,84 94,14 Sum 984,19 100,00 14,20 G0 3894,9 94,84 Sum 4106,84 100,00 Sum 8670,79 100,00 � Strains were made where two different flippase variants were expressed in addition to GNT1 and GNT2 in alg3-alg11 deletion background � The total glycosylation level (sum of peaks) increased ~4x (flippase 1) or ~9x (flippase 2) � The glycan pattern remained good with 93-95% G0 glycans � Glycoengineering in C1 continues to e.g. galactosylation and fucosylation on target proteins like Mabs 19


Production of Biologics in C1 21.11.2019 VTT – beyond the obvious 20


Fermentations for mAbY production Fermentation Vessel Initial (final) Antibody # volume (1) culture volume (1) titre (g/l) 15 10 8.0 (10.5) 8.0 16 1 0.8 (1.1) 6.3 17 1 0.8 (1.1) 6.5 18 1 0.8 (1.1) 7.9 � SDS gel analysis of the mAbY antibody purified from the fermentations by protein A affinity chromatography � ‘start’ depicts the sample loaded to the protein A column, fr4-fr6 are the elution fractions obtained from the chromatography � Sample of CHO-produced mAbY is shown as control � Mass spectrometry analysis showed that both chains were intact 21.11.2019 VTT – beyond the obvious 21


mAbY Binding assay by Biacore T200 Studying the interaction of mAbs in real time Ligand mAbY Immobilization: anti-Human-Fc & anti-Mouse-Fc CHO-produced � The binding properties of C1 produced mAbY were compared to the CHO produced mAbY in a Biacore T200 assay � The C1-produced mAbY and CHO- produced mAbY showed virtually C1-produced indistinguishable binding kinetics � Similar results were obtained with other mAbs 21.11.2019 VTT – beyond the obvious 22


Success in Bispecific mAb expression � Production level 1 g/L in a 6-day fermentation process � Difficult to express in several hosts r: reduced conditions � The function of C1-produced mAb was compared to the CHO- nr: non-reduced conditions produced control in a bioassay o C1-produced purified using only single chromatography step o CHO-produced fully purified � Potency of C1-produced mAb in the bioassay is comparable to the CHO-produced control 21.11.2019 VTT – beyond the obvious 23


Success in expressing high level of ZAPI antigen � Schmallenberg virus antigen coupled with Spytag - difficult-to-express protein in animal cells and microbial systems � First strain had a native C1 promoter in 6xΔ protease strain � Using synthetic promoter (SES) for expression, higher copy number and 8x protease deletion strain increased production six-fold � Development of the protease deficient strain and process conditions increased the titer even further � The produced protein formed nanoparticles with Spycatcher efficiently and showed good immunogenicity in cattle SES promoter C1 promoter 2000 8xΔ strains 6xΔ strain 1830 1800 � The new strain using SES 1600 promoter system in improved 1400 protease deletion background 1200 significantly increased the 1000 production and stability of the 720 800 target antigen 600 Purified antigen (mg/L) antigen Purified 400 120 200 � Up to 1.8 g/L was purified by 0 affinity chromatography 6xΔ 8xΔ 9xΔ 21.11.2019 VTT – beyond the obvious 24


Expression of Fc-Fusion by C1 Production of an Fc-fusion protein in C1 � The Fc-fusion protein was expressed with three synthetic promoters with different strengths � The strains were grown in fermentors at 1 litre scale • Growth and total protein production was similar between the strains • The Fc fusion protein was purified with protein A affinity chromatography Fc-fusion protein Strain Time point concentration (g/L) • Best production level of 12.2 g/l on day 7 was Prom. 1 Day 7 9.0 obtained from promoter 2 Prom. 2 Day 7 12.2 • Expression with an optimized synthetic Prom. 3 Day 7 7.2 promoter resulted in 13.2. g/l production level Optimized Prom. 2 Day 7 13.2 25


Summary � Myceliophthora thermophila C1 is an industrialized protein Product Production level production host that is now developed for therapeutic protein g/L manufacture - with several large biopharma companies entering into collaborations. Mabs 22 � We have identified critical proteases to deal with for therapeutic Fabs 14.5 protein production enhancement and enabled a very significant Fc-fusion proteins 13.2 reduction of the protease load in the production strains. Difficult-to-express � Our glycoengineering program aims at high proportions of human glycoforms G0, G2, FG0 and FG2. Excellent G0 levels have been Bispecific antibodies 1.0 reached through alg3-alg11 deletion strategy. Viral antigens 1.8 � Monoclonal antibodies have been produced in C1 with levels reaching VLPs 0.3 22 g/l and rates up to 3.1 g/l/day. The binding characteristics of the (extracellular prod.) C1-produced antibodies were very similar to CHO-produced controls. Fab fragments have been expressed at levels up to 14.5 g/l and Fc- Bacterial vaccine 6.0 fusion proteins up to 13.2 g/l in a 7-day process. protein � Difficult to express proteins have been produced in C1 at superior levels as compared with other production systems. 21.11.2019 VTT – beyond the obvious 26


Acknowledgements VTT Protein Production Dyadic International Inc. Anne Huuskonen Ronen Tchelet Marika Vitikainen Gabor Keresztes Marilyn Wiebe Mark A. Emalfarb Georg Schmidt Veera Korja Anssi Rantasalo VTT Analytics Kari Koivuranta VTT Biosensors Heli Nygren Kristina Iljin Outi Koivistoinen Natalia Maiorova Hanna Kuusinen Kaisa Roine Karita Viita-aho Merja Aarnio Sirpa Holm LC ESI MS/MS Christopher Landowski Turku Proteomics Facility, University of Turku and Åbo Akademi University Contact Dyadic – [email protected] 21.11.2019 VTT – beyond the obvious 27


THANK YOU [email protected] [email protected] 21.11.2019 VTT – beyond the obvious 28


DYADIC ANNOUNCES ACHIEVING HUMAN LIKE GLYCAN STRUCTURESFROM ITS ENGINEERED C1 CELL LINE

- High G0 Glycosylation Level Driving Program Acceleration -

JUPITER, FL / ACCESSWIRE / November 25, 2019 Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying itsproprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products at flexiblecommercial scales, announced that data presented at the annual PEGS Europe Protein & Antibody Engineering Summit demonstrated that its C1 strain has been successfully glyco-engineered toimpart the core human like G0 glycan structure at high levels. The G0 glycosylation data was presented by Markku Saloheimo, Ph.D., from the VTT Technical Research Centre of Finland Ltd (“VTT”) at the conference in Lisbon, Portugal on Thursday,November 21. The scientific results are outlined in the presentation entitled ''Novel Highly Productive Production System for Biotherapeutics: Filamentous Fungus Myceliophthora thermophila''which is available through Dyadic’s website at: https://www.dyadic.com/wp-content/uploads/2019/11/VTT-Presents-at-PEGS-Lisbon.pdf

“The exceptionally high level of G0 glycans reached through our glycoengineering work with C1 was a very important interim goal in our ongoing C1 research and development program withDyadic where we expect to develop additional C1 strains capable of producing complex human glycoforms, such as G0F, G2, and G2F. Combined with the great advances we have reached inincreasing the production levels of monoclonal antibodies and other target proteins, the glycoengineered C1 strains provide a firm foundation for affordable production of biopharmaceuticals inC1 for patients all over the globe”, said Markku Saloheimo, Senior Principal Scientist of VTT.

“This is a key milestone for our C1 glyco-engineering program where we are targeting the development of C1 strains which are capable of imparting various human like glycoforms such as G0,G0F, G2, and G2F on various types of therapeutic proteins. Reaching G0 glycosylation levels of up to 95% has exceeded our initial objective of 90% and is an important breakthrough for our C1gene expression platform,” said Ronen Tchelet, Ph.D., Dyadic’s Chief Scientific Officer. “These exciting results further support our recent decision to accelerate our C1 glyco-engineering research program which we expect will allow us and our collaborators to apply C1 for broaderuses in the development and manufacture of glyco biologics such as Fc-Fusion proteins and monoclonal antibodies. The very high level of the G0 glycan structure that was achieved will serve asthe building block for additional important mammalian glycan structures being developed for use in biologic products for animal and human health,” said Mark Emalfarb, Dyadic’s Chief ExecutiveOfficer.


About VTT Technical Research Centre of Finland LtdVTT Technical Research Centre of Finland Ltd is one of the leading research and technology organisations in Europe. VTT has a national mandate in Finland. We use our research and knowledge to provideexpert services for our domestic and international customers and partners. We serve both private and public sectors. We have 75 years' experience supporting our clients growth with top-level research andscience-based results. For more information, please visit https://www.vttresearch.com/.

About Dyadic InternationalDyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthorathermophila, named C1. The C1 microorganism, which enables the development and large scale manufacture of low-cost proteins, has the potential to be further developed into a safe and efficient expressionsystem that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and othertechnologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs (such as virus like particles (VLPs) and antigens),monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Recently, Dyadic has also begun exploring the use of its C1 technology and othertechnologies to conduct research, development and commercial activities for the development and manufacturing of Adeno-associated viral vectors (AAV), certain metabolites and other biologic products. Dyadicpursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to create synergy by leveraging Dyadic’s technologies indevelopment and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines,drugs and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and as a result improve access and cost to patients and thehealthcare system, and most importantly, save lives.

Please visit Dyadic’s website at www.dyadic.com for additional information, including details regarding Dyadic’s plans for its biopharmaceutical business.

Safe Harbor Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic’sexpectations, intentions, strategies and beliefs pertaining to future events or future financial performance. Actual events or results may differ materially from those in the forward-looking statements as a result ofvarious important factors, including those described in Dyadic’s most recent filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release, which are based oninformation available to us on the date hereof. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether as a result of new information, future events or otherwise. For a morecomplete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterlyreports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website at www.dyadic.com.

Contact:

Dyadic International, Inc.Mark A. EmalfarbChief Executive OfficerPhone: (561) 743-8333Email: mailto:[email protected]


SECURITIES & EXCHANGE COMMISSION EDGAR...

Documents

Transcript of SECURITIES & EXCHANGE COMMISSION EDGAR...